http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2005539020-A
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D265-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D311-22 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D265-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-536 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-353 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D311-22 |
filingDate | 2003-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2005-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | JP-2005539020-A |
titleOfInvention | Chromone derivatives as matrix metalloproteinase inhibitors |
abstract | The present invention relates to a compound defined by Structural Formula I wherein R 1 , Q, y 2 , y 3 , Y 4 , U 5 , U 6 , U 8 , and R 2 are as defined herein, or The pharmaceutically acceptable salt is provided. The invention also comprises a pharmaceutical composition comprising a compound of structural formula I as defined in the specification or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier, diluent or excipient. provide. The present invention also provides a method of inhibiting MW-13 enzyme in an animal body comprising administering to the animal a compound of structural formula I or a pharmaceutically acceptable salt thereof. The present invention also treats a disease mediated by MNIP13 enzyme in a patient's body, comprising administering to the patient a compound of structural formula I or a pharmaceutically acceptable salt thereof, alone or in the form of a pharmaceutical composition. It also provides a way to do this. The present invention also relates to cardiac disease, multiple sclerosis in a patient's body, comprising administering to the patient a compound of structural formula I or a pharmaceutically acceptable salt thereof, alone or in the form of a pharmaceutical composition, Osteoarthritis and rheumatoid arthritis, degenerative joint inflammation and arthritis other than rheumatoid arthritis, heart failure, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal disease, psoriasis, atherosclerosis Also provided are methods of treating diseases such as arteriosclerosis and osteoporosis. The present invention also provides a combination comprising a compound of structural formula I or a pharmaceutically acceptable salt thereof together with another pharmaceutically active ingredient as described in the specification. |
priorityDate | 2002-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 504.